No interaction was found between HPD and the immunotherapy drug (p = 0.440), GRIm (p = 1) or any of its variables, i.e., LIPI of poor prognosis (p = 1.000), number of previous treatments (p = 0.151), gender (p = 1.000), age (p = 0.072), performance status (p = 0.189), tumor histology (p = 1.000), PD-L1 tumor expression (p = 0.599), number of affected organs (p = 0.707) or liver metastases (p = 0.707). This evidence concerns the gene CD274 and medical procedure.